Published in Mental Health Weekly Digest, January 25th, 2010
In October 2009, Vanda and Novartis Pharma AG entered into an agreement, pursuant to which Novartis has exclusive U.S. and Canadian commercialization rights to Fanapt™. Under this agreement, Vanda received an upfront payment of $200 million and is eligible for future payments totaling up to $265 million upon the achievement of certain commercial and development milestones for Fanapt™, as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Weekly Digest
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.